Evaluating Hydroxychloroquine for Treating Genetic Childrens Interstitial Lung Disease in a Randomized Study

What this Trial Is About

This research aims to evaluate the effectiveness and safety of hydroxychloroquine HCQ in children with interstitial lung diseases chILD caused by genetic factors. chILD is a rare group of chronic lung disorders with high health risks, often linked to gene variations affecting surfactant proteins. This randomized controlled trial focuses on children under 18 years with genetically confirmed chILD to better understand HCQs role in treatment. Participants are randomly assigned to one of two groups one group receives hydroxychloroquine orally at a dose of 10 mgkg twice daily for 12 months, with a maximum daily dose of 400 mg. The other group serves as a control and does not receive hydroxychloroquine. This study spans a full year of treatment to observe potential changes and effects. During the study, researchers will monitor participants oxygenation status at 1, 3, 6, and 12 months. They will also evaluate improvements in clinical symptoms at the same intervals. Participants are expected to be clinically stable before joining, with no recent medication changes or HCQ use. Safety and health monitoring will continue throughout the trial, which is planned to end in April 2027.

Hydroxychloroquine in Children's Interstitial Lung Diseases With Genetic Causes